Drug Profile
Sofituzumab vedotin
Alternative Names: Anti-MUC16 ADC MMAE; Anti-MUC16 mAb MMAE; Anti-MUC16 MMAE ADC; Anti-MUC16 monoclonal antibody MMAE; Anti-MUC16 monoclonal antibody monomethyl auristatin E conjugate; Anti-MUC16 monoclonal antibody vedotin; DMUC-5754A; MMAE anti-MUC16 mAb; MMAE anti-MUC16 monoclonal antibody conjugate; Monomethyl auristatin E anti-MUC16 monoclonal antibody conjugate; RG-7458; Vedotin anti-MUC16 monoclonal antibodyLatest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator Genentech
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer